- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04233060
A Study of CS3005 in Advanced Solid Tumors
April 26, 2022 updated by: CStone Pharmaceuticals
A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors
A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with Advanced Solid Tumors
Study Overview
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2031
- Scientia Clinical Research Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
General
- Be willing and able to provide written informed consent form for the trial.
- Male or female between 18 to 75 years of age.
- Ability to comply with requirements of the protocol, as assessed by the investigator.
- Subjects who were histologically confirmed advanced solid tumor shall have progressed disease and/or experienced intolerance from prior standard therapies, or for whom no standard of care (SoC) therapies exist.
- Subject must have at least one measurable lesion by CT or MRI; radiographic tumor assessment should be performed within 28 days prior to the first dose of study treatment.
- ECOG performance status score of 0 or 1
- Prior immunotherapy is allowed
- Subjects who have previously received anti-tumor therapy will only be enrolled if the toxicities from the previous treatment have returned to the baseline level or NCI CTCAE v 5.0 grade ≤1.
- Subject must have adequate organ function as indicated by the following laboratory values, G-CSF or other relevant medical support within 14 days before the administration of the investigational product
- Subjects with active hepatitis B or active hepatitis C must receive antiviral treatment and pass the HBV DNA titer test and HCV RNA test before being enrolled. The subject should be willing to continue effective anti-viral treatment during the study.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test result. Either Female or male subjects must agree to use adequate contraceptive measures.
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Patients with any condition that impairs their ability to take oral medication.
- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Subjects with active, known, or suspected autoimmune disease in the past 3 years prior to the start of treatment.
- History of active tuberculosis, both pulmonary and extrapulmonary.
- Clinically Significant history of cardiac disease within 6 months prior to 1st dosing, myocardial infarction within the previous year, or current cardiac ventricular arrhythmias requiring medication.
- Subjects with ascites, pleural effusion, pericardial effusion which cannot be reversed by appropriate interventions.
- Subjects with any active infections requiring systemic therapy within 2 weeks prior to the initiation of the study treatment.
- Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.
- History of organ transplant that requires the use of immunosuppressive treatment.
- For post immunotherapy patients, with prior ≥ Grade 3, serious, or life-threatening immune-mediated reactions following prior anti-PD-(L)1 or other immune-oncology therapies.
- Subjects who have received systemic anti-tumor treatments 21 days prior to the initiation of the study treatment.
- Subjects who have received treatment with approved anti-tumor Chinese herbal medicine or Chinese prepared.
- Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications.
- Has received treatment with non-selective adenosine antagonist or A2a receptor antagonist.
- Concurrent administration of strong inhibitors or inducers of CYP3A4 and CYP1A2 is not permitted
For more information regarding trial participation, please contact at cstonera@cstonepharma.com
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CS3005
|
CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: From the day of first dose to 30 days (±7 days) after last dose of CS3005, up to 2 years
|
From the day of first dose to 30 days (±7 days) after last dose of CS3005, up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Fei Li, PhD, CStone Pharmaceuticals
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 10, 2020
Primary Completion (ACTUAL)
January 31, 2021
Study Completion (ACTUAL)
February 17, 2021
Study Registration Dates
First Submitted
January 15, 2020
First Submitted That Met QC Criteria
January 15, 2020
First Posted (ACTUAL)
January 18, 2020
Study Record Updates
Last Update Posted (ACTUAL)
April 27, 2022
Last Update Submitted That Met QC Criteria
April 26, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS3005-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor